ClinicalTrials.gg
Not yet recruitingNCT07897175Updated Oct 27, 2026

Effects of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Cognition, Dual-Task Performance, and Interoceptive Accuracy

An interventional study of Sham Stimulation and taVNS 30 Hz in Cognition and Healthy Volunteers, sponsored by Toros University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Toros University · Not applicable, Interventional, and Basic science

How we know

Updated Oct 27, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study aims to determine the simultaneous effects of transcutaneous auricular vagus nerve stimulation (taVNS) at two frequencies (30 Hz and 100 Hz) compared to sham stimulation on cognitive functions, dual-task performance, and interoceptive accuracy in healthy adults. taVNS non-invasively activates vagal afferent fibers through electrical stimulation of the outer ear (cymba conchae and tragus), which are exclusively innervated by the auricular branch of the vagus nerve. Its proposed mechanism involves activation of the locus coeruleus-norepinephrine system and insular/prefrontal projections, providing a putative neurobiological basis for cognitive modulation. Ninety healthy volunteers (18-45 years) will be randomly assigned to one of three parallel groups: sham taVNS (n=30), active 30 Hz taVNS (n=30), or active 100 Hz taVNS (n=30). Each participant completes two sessions separated by one week: Session 1 (baseline, no stimulation) and Session 2 (experimental, stimulation active). Assessments include dual-task cost (3-Meter Tandem Walk Test with serial subtraction), executive function (Stroop Test), processing speed (Deary-Liewald Reaction Time Task), interoceptive accuracy (Heartbeat Counting Task), and heart rate variability (Polar H10). Sleep quality (PSQI), depression (BDI), physical activity (IPAQ-SF), and fatigue (Chalder Fatigue Scale) are measured at baseline as potential moderators. This is the first double-blind, sham-controlled study to simultaneously evaluate the effects of taVNS on these three constructs within a single experimental design, and the comparative frequency analysis (30 Hz vs 100 Hz) will contribute to parameter optimization for taVNS applications.

Read the detailed description

BACKGROUND AND RATIONALE The vagus nerve (cranial nerve X) is the longest and most widely distributed component of the parasympathetic nervous system. The auricular branch of the vagus nerve innervates specific anatomical regions of the outer ear, particularly the cymba conchae. Transcutaneous auricular vagus nerve stimulation (taVNS) leverages this anatomy to non-invasively activate vagal afferents without surgical implantation. The core mechanism involves projections from stimulated vagal afferents to the nucleus tractus solitarius (NTS), with subsequent signal relay to the locus coeruleus-norepinephrine (LC-NE) system, nucleus raphe, insula, and prefrontal cortex. A meta-analysis of 19 studies reported a small but statistically significant effect of taVNS on overall cognitive performance (weighted effect size = 0.21), with significant effects particularly for executive functions. No published study has simultaneously evaluated taVNS effects on cognitive function, dual-task performance, and interoceptive accuracy within the same design. STUDY DESIGN Single-center, prospective, double-blind, parallel-group, sham-controlled randomized trial. Participants are randomized via a web-based tool to one of three groups (1:1:1). Double blinding is achieved by keeping both the participant and the outcome assessor blinded to group allocation; stimulation is administered by a separate researcher not involved in assessments. The CONSORT checklist will be followed. PROTOCOL Session 1 (Baseline): Cognitive function (Stroop, Deary-Liewald), dual-task performance (3-Meter Tandem Walk Test), interoceptive accuracy (Heartbeat Counting Task), and HRV (Polar H10) are assessed without stimulation. Baseline questionnaires (PSQI, BDI, IPAQ-SF, Chalder) and MMSE screening are also administered. Session 2 (Experimental, 1 week later): The same outcome measures are re-assessed during active or sham taVNS administration. Within-group change (Δ = Session 2 - Session 1) and between-group comparisons (ΔSham vs. Δ30 Hz vs. Δ100 Hz) are the primary analyses. STIMULATION PARAMETERS Device: Vagustim® non-invasive stimulation device (CE No: 2460; Vagustim Health Technologies Inc., Turkey). Electrode placement: bilateral cymba conchae and tragus. Pulse width: 250 µs. Mode: continuous. Intensity: perceptible but sub-pain threshold. Groups: Sham (same electrode placement, no current); 30 Hz active; 100 Hz active. OUTCOME MEASURES Primary outcomes assessed at both sessions: (1) Dual-Task Cost (%) on 3-Meter Tandem Walk Test with serial subtraction by 3s; (2) Stroop effect (response time and accuracy); (3) Simple and Choice Reaction Time (Deary-Liewald Task); (4) Interoceptive Accuracy Score (Heartbeat Counting Task - 25, 35, 45-second intervals; Schandry 1981 formula). Secondary outcome assessed at both sessions: Heart Rate Variability (1-min resting Polar H10 recording). Baseline-only assessments: Pittsburgh Sleep Quality Index, Beck Depression Inventory, IPAQ-Short Form, Chalder Fatigue Scale, Mini-Mental State Examination (screening criterion). STATISTICAL ANALYSIS Two-way repeated-measures ANOVA (within-between interaction) for primary analysis; Bonferroni-corrected post-hoc comparisons. Effect sizes reported as partial eta squared (η²). Multiple linear regression to identify moderators of taVNS response. Analyses conducted in IBM SPSS Statistics v27.

02

Conditions studied

  • Cognition
  • Healthy Volunteers

Keywords

  • transcutaneous auricular vagus nerve stimulation;
  • cognitive function
  • heartbeat counting task
  • reaction time
03

In context

Lead sponsor

Toros University is the lead sponsor of 21 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age 18-45 years 2. (MMSE) score >24 3. Willing to participate; signed written 4. No uncorrected vision problems (glasses or contact lenses acceptable) 5. No communication difficulties; native Turkish speaker

Exclusion criteria

Exclusion Criteria:

  • 1. Cardiovascular disease or history (arrhythmia, conduction block, hypertension, cardiac diagnosis) 2. Any implanted electronic device or metal implant in the head/neck (pacemaker, cochlear implant, ventricular shunt, etc.) 3. Neurological disease or history of neurological procedures (epilepsy, stroke, , migraine, brain surgery, progressive neurological disease) 4. Psychiatric diagnosis (schizophrenia, bipolar disorder, major depressive disorder, OCD, etc.) 5. History of vagotomy or prior vagus nerve stimulation 6. Current use of medications affecting the autonomic or central nervous system (beta-blockers, antiarrhythmics, antidepressants, antiepileptics, sedatives, etc.) 7. Systemic disease affecting autonomic function (diabetes, etc.) 8. Local conditions at stimulation site: acute tinnitus, ear or facial pain, ear trauma, skin lesion or infection, anatomical anomaly, or ear piercing at stimulation site 9. Chronic or acute musculoskeletal pain (neck/low back pain, fibromyalgia, joint disease, etc.) 10. Pregnancy or breastfeeding 11. Alcohol or substance use disorder 12. Concurrent enrollment in another interventional study 13. Vigorous physical exercise within 24 hours before assessment 14. Inability to understand or adhere to study protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Sham comparator
    Sham taVNS

    Participants receive sham stimulation via Vagustim® device with the same bilateral electrode placement at cymba conchae and tragus, but with no electrical current delivered. Electrode placement and session duration are identical to active groups

    Device: Sham Stimulation

  • Experimental
    Active taVNS - 30 Hz

    Participants receive active transcutaneous auricular vagus nerve stimulation at 30 Hz via Vagustim® device, bilaterally applied to cymba conchae and tragus, at sub-pain perceptible intensity, throughout the experimental session.

    Device: taVNS 30 Hz

  • Experimental
    Active taVNS - 100 Hz

    Participants receive active transcutaneous auricular vagus nerve stimulation at 100 Hz via Vagustim® device, bilaterally applied to cymba conchae and tragus, at sub-pain perceptible intensity, throughout the experimental session.

    Device: taVNS 100 Hz

Interventions

  • DeviceSham Stimulation

    Sham transcutaneous auricular vagus nerve stimulation delivered via Vagustim® non-invasive stimulation device (CE No: 2460; Vagustim Health Technologies Inc., Turkey). Electrode placement is identical to active groups: bilateral cymba conchae and tragus using custom-sized auricular electrodes (small/medium/large). The device is switched on and electrodes are positioned in the same manner, but no electrical current is delivered. Session duration and all procedural steps are identical to active arms to maintain blinding. Participants are not informed of group allocation. The outcome assessor is blinded to group assignment throughout the study.

  • DevicetaVNS 30 Hz

    Active transcutaneous auricular vagus nerve stimulation at 30 Hz delivered via Vagustim® non-invasive stimulation device (CE No: 2460; Vagustim Health Technologies Inc., Turkey). Electrode placement: bilateral cymba conchae and tragus using custom-sized auricular electrodes (small/medium/large). Parameters: frequency 30 Hz, pulse width 250 µs, continuous mode, current intensity individually titrated to a perceptible but sub-pain threshold. Stimulation is applied online (throughout the experimental session) during all outcome assessments. The outcome assessor is blinded to group allocation; stimulation is administered by a separate researcher not involved in assessments.

  • DevicetaVNS 100 Hz

    Active transcutaneous auricular vagus nerve stimulation at 100 Hz delivered via Vagustim® non-invasive stimulation device (CE No: 2460; Vagustim Health Technologies Inc., Turkey). Electrode placement: bilateral cymba conchae and tragus using custom-sized auricular electrodes (small/medium/large). Parameters: frequency 100 Hz, pulse width 250 µs, continuous mode, current intensity individually titrated to a perceptible but sub-pain threshold. Stimulation is applied online (throughout the experimental session) during all outcome assessments. The outcome assessor is blinded to group allocation; stimulation is administered by a separate researcher not involved in assessments.

06

What researchers measure

Primary outcomes

  1. Dual-Task Cost on 3-Meter Tandem Walk Test

    Dual-Task Cost (DTC, %) quantifies the decrement in tandem walking performance when simultaneously performing serial subtraction (counting backward by 3s from a 3-digit number). DTC (%) = \[(single-task time - dual-task time) / single-task time\] × 100. Higher DTC indicates greater cognitive-motor interference.

    Time frame: Session 1 (Baseline, no stimulation) and Session 2 (1 week later, during taVNS or sham)

  2. Stroop test

    Executive function assessed via Stroop Test (Stroop Anchor Form). The Stroop effect is the difference in response time and accuracy between the color-word incongruent and congruent conditions, reflecting inhibitory control capacity.

    Time frame: Session 1 (Baseline) and Session 2 (1 week later, during taVNS or sham)

  3. Simple and Choice Reaction Time - Deary-Liewald Task

    Processing speed assessed using the Deary-Liewald Reaction Time Task administered via psytoolkit.org. Two conditions: Simple Reaction Time (SRT: respond to single stimulus appearing on blue background) and Choice Reaction Time (CRT: respond to one of four stimuli with the corresponding key). Inter-stimulus interval randomized between 1-3 seconds.

    Time frame: Session 1 (Baseline) and Session 2 (1 week later, during taVNS or sham)

  4. Heartbeat Counting Task Score (Interoceptive Accuracy)

    Objective interoceptive accuracy assessed using the Schandry (1981) Heartbeat Counting Task. Participants silently count their own heartbeats during 25-, 35-, and 45-second intervals without external cues. Reported counts are compared with actual heart rate recorded via Polar H10 sensor. Accuracy score = 1 - \[Σ(\|reported - actual\| / actual)\] / 3. Scores range 0-1; higher scores indicate greater interoceptive accuracy.

    Time frame: Session 1 (Baseline) and Session 2 (1 week later, during taVNS or sham)

Secondary outcomes

  1. Resting Heart Rate Variability

    HRV assessed as an index of autonomic nervous system regulation using Polar H10 heart rate sensor (Polar Electro Oy, Kempele, Finland) synchronized via Bluetooth with the "ECG Analysis for Polar H10" smartphone application. Participants rest in a supported seated position for 1 minute after sensor calibration. Time-domain and frequency-domain HRV indices extracted.

    Time frame: Session 1 (Baseline) and Session 2 (1 week later, during taVNS or sham)

07

Study locations

1 site
  • Toros University 45 Evler Campus
    Mersin, 33140, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Oct 27, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
May 1, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07897175
Lead sponsor
Toros University
Responsible party
Ece Ekici (Research Assisstant, Toros University) — Principal investigator
First posted
Oct 27, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Ece EKİCİ, MSc
Contact
ekiciece@gmail.com
+905300733826
Öznur TUNCA, PhD
study chair · Hacettepe University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion